Long-term treatment results of hepatoblastoma at a single institution in Taiwan

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 10, 2009, Pages 718-722

  Hou, Jen Yin ^a   Liu, Hsi Che ^a,b,c   Yeh, Ting Chi ^a,b   Chen, Shu Huey ^a   Wang, Lin Yen ^a   Sheu, Jin Cherng ^a,c   Liang, Der Cherng ^a  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Chemotherapy; Cisplatin; Epirubicin; Hepatoblastoma

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; VINCRISTINE;

ARTICLE; BECKWITH WIEDEMANN SYNDROME; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEBRILE NEUTROPENIA; FEMALE; HEPATITIS B; HEPATOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFANT; INFECTION; LONG TERM CARE; MALE; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRECOCIOUS PUBERTY; PREMATURITY; PRESCHOOL CHILD; PRIORITY JOURNAL; SURVIVAL RATE; TAIWAN; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAUSE OF DEATH; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HEPATOBLASTOMA; HUMANS; INFANT; LONGITUDINAL STUDIES; MALE; NEUTROPENIA; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAIWAN; TREATMENT OUTCOME;

EID: 70349811290     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181b6db88     Document Type: Article

References (22)

1. Darbari A, Sabin KM, Shapiro CN, et al.. Epidemiology of primary hepatic malignancies in U.S. children. Hepatology. 2003;38:560-566.
2. Tanimura M, Matsui I, Abe J, et al.. Increased risk of hepatoblastoma among immature children with a lower birth weight. Cancer Res. 1998;58:3032-3035.
3. Ortega JA, Douglass EC, Feusner JH, et al.. Randomized comparison of cisplatin/vincristine/fiuorouracil and cisplatin/ continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol. 2000;18:2665-2675.
4. Pritchard J, Brown J, Shafford E, et al.. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: A successful approach-results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol. 2000;18:3819-3828.
5. Perilongo G, Shafford E, Plaschkes J. SIOPEL trials using preoperative chemotherapy in hepatoblastoma. Lancet Oncol. 2000;1:94-100.
6. Sasaki F, Matsunaga T, Iwafuchi M, et al.. Outcome of hepatoblastoma treated with the JPLT-1 (Japanese Study Group for Pediatric Liver Tumor) Protocol-1: A report from the Japanese Study Group for Pediatric Liver Tumor. J Pediatr Surg. 2002;37:851-856.
7. Von Schweinitz D, Byrd DJ, Hecker H, et al.. Eficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Study Committee of the Cooperative Paediatric Liver Tumour Study HB89 of the German Society for Paediatric Oncology and Haematology. Eur J Cancer. 1997;33:1243-1249.
8. Fuchs J, Rydzynski J, Von Schweinitz D, et al.. Pretreatment prognostic factors and treatment results in children with hepatoblastoma: A report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer. 2002;95:172-182.
9. Ehrlich PF, Greenberg ML, Filler RM. Improved long-term survival with preoperative chemotherapy for hepatoblastoma. J Pediatr Surg. 1997;32:999-1002; discussion 1002-1003.
10. Holton CP, Burrington JD, Hatch EI. A multiple chemotherapeutic approach to the management of hepatoblastoma. A preliminary report. Cancer. 1975;35:1083-1087.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
12. Brock PR, Bellman SC, Yeomans EC, et al.. Cisplatin ototoxicity in children: A practical grading system. Med Pediatr Oncol. 1991;19:295-300.
13. Blouin P, Brugieres L, Tabone MD, et al.. Carboplatinepirubicin regimen for the treatment of hepatoblastoma. Pediatr Blood Cancer. 2004;42:149-154.
14. Kazzi NJ, Chang CH, Roberts EC, et al.. Fetal hepatoblastoma presenting as nonimmune hydrops. Am J Perinatol. 1989;6: 278-280.
15. Shih JC, Tsao PN, Huang SF, et al.. Antenatal diagnosis of congenital hepatoblastoma in utero. Ultrasound Obstet Gynecol. 2000;16:94-97.
16. Fraumeni JF Jr, Rosen PJ, Hull EW, et al.. Hepatoblastoma in infant sisters. Cancer. 1969;24:1086-1090.
17. Napoli VM, Campbell WG Jr. Hepatoblastoma in infant sister and brother. Cancer. 1977;39:2647-2650.
18. Ito E, SatoY, Kawauchi K, et al. Type 1a glycogen storage disease with hepatoblastoma in siblings. Cancer. 1987;59:1776-1780.
19. Surendran N, Radhakrishna K, Chellam VG. Hepatoblastoma in siblings. J Pediatr Surg. 1989;24:1169-1171.
20. Blaker H, Hofmann WJ, Rieker RJ, et al. Beta-catenin accumulation and mutation of the CTNNB1 gene in hepatoblastoma. Genes Chromosomes Cancer. 1999;25:399-402.
21. Bertolini P, Lassalle M, Mercier G, et al. Platinum compoundrelated ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol. 2004;26:649-655.
22. French Epirubicin Study Group. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fiuorouracil, and either doxorubicin or epirubicin. J Clin Oncol. 1988;6:679-688.